Glenmark gains on receiving ANDA tentative nod for Nintedanib capsules

The company’s current portfolio consists of 172 products, authorised for distribution in the US marketplace while 44 ANDAs are still pending approval with USFDA.

Glenmark Pharmaceuticals Ltd has received tentative approval by United States Food & Drug Administration (USFDA) for its Nintedanib capsules, 100 mg & 150 mg, which is the generic version of Ofev®1 capsules, 100 mg and 150 mg, produced by Boehringer Ingelheim Pharmaceuticals, Inc.  

According to IQVIA sales data for the past 12 months ending April 2021, Ofev® capsules, 100 mg & 150 mg market achieved annual sales of approximately over $1.6 billion. The market size of these capsules is huge, which is sure to benefit the company.  

The company’s current portfolio consists of 172 products, authorised for distribution in the US marketplace while 44 ANDAs are still pending approval with USFDA. In addition to these internal filings, it continues to identify and explore external development partnerships to supplement as well as accelerate the growth of its existing pipeline and portfolio for the betterment of society. It currently operates in more than 50 countries.  

At 10.30 am on Friday, the share price of the company was trading 1.65 per cent higher at Rs 641.10 on BSE. 

---